Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.

Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, Pakakasama S, Hongeng S.

J Pediatr Hematol Oncol. 2013 May;35(4):e138-43. doi: 10.1097/MPH.0b013e3182707fc5.

PMID:
23274376
2.

[Genetic background of cisplatin induced ototoxicity].

Jurajda M, Talach T, Kostřica R, Lakomý R, Kocák I, Cvanová M.

Klin Onkol. 2012;25(3):184-7. Czech.

PMID:
22724567
3.

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, am Zehnhoff-Dinnesen A.

Pharmacogenomics J. 2008 Feb;8(1):23-8. Epub 2007 Apr 24.

PMID:
17457342
4.

Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.

Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD.

J Clin Oncol. 2007 Feb 20;25(6):708-14. Epub 2007 Jan 16.

PMID:
17228018
5.

Pharmacogenomics of cisplatin-induced ototoxicity.

Mukherjea D, Rybak LP.

Pharmacogenomics. 2011 Jul;12(7):1039-50. doi: 10.2217/pgs.11.48. Review.

6.

Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.

Pediatr Blood Cancer. 2012 Jul 15;59(1):144-8. doi: 10.1002/pbc.24138. Epub 2012 Mar 19.

7.

Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jürgens H, Lamprecht-Dinnesen A.

Anticancer Drugs. 2000 Sep;11(8):639-43.

PMID:
11081456
8.

Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.

Olgun Y, Aktaş S, Altun Z, Kırkım G, Kızmazoğlu DÇ, Erçetin AP, Demir B, İnce D, Mutafoğlu K, Demirağ B, Ellidokuz H, Olgun N, Güneri EA.

Int J Pediatr Otorhinolaryngol. 2016 Nov;90:64-69. doi: 10.1016/j.ijporl.2016.09.001. Epub 2016 Sep 4.

PMID:
27729156
9.

Cisplatin-induced hearing loss: the need for a long-term evaluating system.

Yasui N, Adachi N, Kato M, Koh K, Asanuma S, Sakata H, Hanada R.

J Pediatr Hematol Oncol. 2014 May;36(4):e241-5. doi: 10.1097/MPH.0000000000000028.

PMID:
24072246
10.

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium.

Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8. Erratum in: Nat Genet. 2013 May;45(5):578.

PMID:
19898482
11.

Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.

Cancer Invest. 2005;23(3):201-7.

PMID:
15945505
12.

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-Ariznabarreta L, Benítez J, González-Neira A.

Pharmacogenomics J. 2009 Oct;9(5):347-53. doi: 10.1038/tpj.2009.19. Epub 2009 May 12.

PMID:
19434073
13.

Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.

Lafay-Cousin L, Purdy E, Huang A, Cushing SL, Papaioannou V, Nettel-Aguirre A, Bouffet E.

Pediatr Blood Cancer. 2013 Feb;60(2):287-92. doi: 10.1002/pbc.24307. Epub 2012 Sep 21.

PMID:
23002030
14.

Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.

Gupta AA, Capra M, Papaioannou V, Hall G, Maze R, Dix D, Weitzman S.

J Pediatr Hematol Oncol. 2006 Feb;28(2):91-4.

PMID:
16462581
15.

Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.

Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.

J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55.

PMID:
15454836
16.

Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.

Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, van Grotel M, van den Heuvel-Eibrink MM; DCOG-LATER, The Netherlands.

Eur J Cancer. 2016 Dec;69:77-85. doi: 10.1016/j.ejca.2016.09.023. Epub 2016 Nov 4.

PMID:
27821322
17.

Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.

Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, Daniel SJ.

Pediatr Blood Cancer. 2014 Nov;61(11):2012-7. doi: 10.1002/pbc.25123. Epub 2014 Jun 29.

PMID:
24976616
18.

[Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].

Biró K.

Magy Onkol. 2009 Sep;53(3):279-83. doi: 10.1556/MOnkol.53.2009.3.8. Hungarian.

19.

Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.

Rednam S, Scheurer ME, Adesina A, Lau CC, Okcu MF.

Pediatr Blood Cancer. 2013 Apr;60(4):593-8. doi: 10.1002/pbc.24366. Epub 2012 Oct 12.

20.

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.

Li Y, Womer RB, Silber JH.

Eur J Cancer. 2004 Nov;40(16):2445-51.

PMID:
15519518

Supplemental Content

Support Center